Needham analyst David Saxon reiterated a Buy rating on CryoPort (NASDAQ:CYRX) Inc on Wednesday, setting a price target of $77, which is approximately 39.44% above the present share price of $55.22.
Saxon expects CryoPort Inc to post earnings per share (EPS) of -$1.32 for the second quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in CryoPort, with an average price target of $79.25.
The analysts price targets range from a high of $84 to a low of $75.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $48.36 million and a net profit of -$9.85 million. The company's market cap is $2.52 billion.
According to TipRanks.com, Needham analyst David Saxon is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 38.0% and a 87.50% success rate.
CryoPort, Inc. engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers. It offers personalized medicine, immunotherapies, cellular therapies, CAR T-cell therapies, stem cell therapies, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to certain ranges of precision-controlled temperatures. The company was founded on May 25, 1990 and is headquartered in Irvine, CA.